

JC10 Rec'd PCT/PTO 26 DEC 2001 *pc*

PATENT
Attorney Docket No. 212691

#~~3~~5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zaleski et al.

Group Art Unit: Unassigned

Application No. 09/913,924

Examiner: Unassigned

Filed: August 20, 2001

For: COMPOUNDS, COMPOSITIONS, AND
METHODS FOR PHOTODYNAMIC
THERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

- ☒ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

- ☐ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
- or*
- ☐ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

Copies of the References

- ☒ Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
- ☐ A copy of the foreign search report is enclosed herewith.
- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLICATIONS		Status (<i>check one</i>)		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

Statement under 37 CFR 1.97(e)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No fee is owed by the applicant(s).
- ☐ The **IDS Fee of \$180** under 37 CFR 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$.
- ☐ Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)


Authorization to Charge Additional Fees

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

In re Appln. of Zaleski et al.
Application No. 09/913,924

Instructions as to Overpayment

☒ Credit Account No. 12-1216.
☐ Refund



Salim. A. Hasan, Reg. No. 38,175
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: November 26, 2001

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date: November 26, 2001 J. Mikitiouh

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/913,924
Filing Date	August 20, 2001
First Named Inventor	Jeffrey M. ZALESKI
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	212691

Sheet 1 of 7

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	AF	09/962,388		Zaleski et al.		09/25/01

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	AG	ALI et al., "Metal Complexes as Photo- and Radiosensitizers," <i>Chem. Rev.</i> , 99, 2379-2450 (1999)		
	AH	BASAK et al., "The Synthesis and Reactivity of Novel Azetidiny Enediynes," <i>Chem. Commun.</i> , 749-750 (1996)		
	AI	BERGMAN, "Reactive 1,4-Dehydroaromatics," <i>Accounts of Chemical Research</i> , 6, 25-31 (1973)		
	AJ	BONADIES et al., "Vanadium Phenolates as Models for Vanadium in Biological Systems. 1. Synthesis, Spectroscopy, and Electrochemistry of Vanadium Complexes of Ethylenebis [(o-hydroxyphenyl)glycine] and Its Derivatives," <i>J. Am. Chem. Soc.</i> , 108, 4088-4095 (1986)		
	AK	BONNETT, "Photosensitizers of the Porphyrin and Phtalocyanine Series for Photodynamic Therapy," <i>Chem. Soc. Reviews</i> , 24, 19-33 (1995)		
	AL	BOYLE et al., "Structure and Biodistribution Relationships of Photodynamic Sensitizers," <i>Photochemistry and Photobiology</i> , 64 (3), 469-485 (1996)		
	AM	BRANCA et al., "Formation and Structure of the Tris(catecholato)vanadate(IV) Complex in Aqueous Solution," <i>Inorg. Chem.</i> , 29, 1586-1589 (1990)		
	AN	CHAPMAN et al., "9,10-Dehydroanthracene. A Derivative of 1,4-Dehydrobenzene," <i>J. Am. Chem. Soc.</i> , 98 (18), 5703-5705 (1976)		
	AO	CHRISTNER et al., "Unmasking the Chemistry of DNA Cleavage by the Esperamicins: Modulation of 4'-Hydrogen Abstraction and Bistranded Damage by the Fucose-Anthranilate Moiety," <i>J. Am. Chem. Soc.</i> , 114, 8763-8767 (1992)		
	AP	CHURCHER et al., "Synthesis of the Enediyne Aglycon (±)-Calicheamicinone," <i>J. Am. Chem. Soc.</i> , 120, 3518-3519 (1998)		

Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/913,924
Filing Date	August 20, 2001
First Named Inventor	Jeffrey M. ZALESKI
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	212691

Sheet 2 of 7

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	AQ	CUMMINGS et al., "Luminescent Platinum (II) Complexes of Quinoxaline-2,3-dithiolate," <i>Inorg. Chem.</i> , 34, 2007-2014 (1995)		
	AR	CUMMINGS et al., "Tuning the Excited-State Properties of Platinum (II) Diimine Dithiolate Complexes," <i>J. Am. Chem. Soc.</i> , 118, 1949-1960 (1996)		
	AS	DAI et al., "Synthesis and DNA Clavage Study of a 10-Membered Ring Eneidyne Formed via Allylic Rearrangement," <i>J. Org. Chem.</i> , 64, 682-683 (1999)		
	AT	EVENZAHAV et al., "Photochemical Rearrangement of Endiynes: Is a "Photo-Bergman" Cyclization a Possibility?" <i>J. Am. Chem. Soc.</i> , 120, 1835-1841 (1998)		
	AU	FUNK et al., "Photochemical Cycloaromatization Reactions of <i>ortho</i> -Dialkynylarenes: A New Class of DNA Photocleaving Agents," <i>J. Am. Chem. Soc.</i> , 118, 3291-3292 (1996)		
	AV	GOLIK et al., "Esperamicins, a Novel Class of Potent Antitumor Antibiotics. 2. Structure of Esperamicin X," <i>J. Am. Chem. Soc.</i> , 109, 3461-3462 (1987)		
	AW	GOLIK et al., "Esperamicins, a Novel Class of Potent Antitumor Antibiotics. 3. Structures of Esperamicins A1, A2, and A1b," <i>J. Am. Chem. Soc.</i> , 109, 3462-3464 (1987)		
	AX	HANGELAND et al., "Specific Abstraction of the 5'(S)- and 4'-Deoxyribosyl Hydrogen Atoms from DNA by Calicheamicin γ_1 ," <i>J. Am. Chem. Soc.</i> , 114, 9200-9202 (1992)		
	AY	HOLMES et al., "Models for the Binding Site in Bromoperoxidase: Mononuclear Vanadium (V) Phenolate Complexes of the Hydridotris(3,5-dimethylpyrazolyl)borate Ligand," <i>Inorg. Chem.</i> , 30, 1231-1235 (1991)		
	AZ	KANEKO et al., "Photochemical Cycloaromatization of Non-Benzenoid Eneidiynes," <i>Angew. Chem. Int. Ed.</i> , 38 (9), 1267-1268 (1999)		
	BA	KIM et al., "Rapid Bergman Cyclization of 1,2-Diethynylheteroarenes," <i>J. Org. Chem.</i> , 63, 8229-8234 (1998)		
	BB	KONIG et al., "Activation of Macrocyclic Biaryl-Eneidiynes by Metal Ion Coordination," <i>Angew. Chem. Int. Ed. Engl.</i> , 34 (22), 2538-2540 (1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/913,924
Filing Date	August 20, 2001
First Named Inventor	Jeffrey M. ZALESKI
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	212691

Sheet 3 of 7

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	B C	KONIG et al., "Synthesis, Structure, and Reactivity of Enediyne Macrocycles," <i>J. Org. Chem.</i> , 61, 4258-4261 (1996)		
	B D	KUSAKABE et al., "Conformation-Selective DNA Strand Breaks by Dynemicin: A Molecular Wedge into Flexible Regions of DNA," <i>Biochemistry</i> , 32, 11669-11675 (1993)		
	B E	LEE et al., "Calicheamicins, a Novel Family of Antitumor Antibiotics. 4. Structure Elucidation of Calicheamicins β_1^{Br} , γ_1^{Br} , α_2^I , α_3^I , β_1^I , γ_1^I , and δ_1^I ," <i>J. Am. Chem. Soc.</i> , 114, 985-997 (1992)		
	B F	LEET et al., "Chemistry and Structure Elucidation of the Kedarcidin Chromophore," <i>J. Am. Chem. Soc.</i> , 115, 8432-8443 (1993)		
	B G	LI et al., "Vanadium Complexes of the Tridentate Schiff Base Ligand <i>N</i> -Salicylidene- <i>N'</i> -(2-hydroxyethyl)ethylenediamine: Acid-Base and Redox Conversion between Vanadium (IV) and Vanadium (V) Imino Phenolates," <i>Inorg. Chem.</i> , 27, 4657-4664 (1988)		
	B H	LOCKHART et al., "Evidence for the Reactive Spin State of 1,4-Dehydrobenzenes," <i>J. Am. Chem. Soc.</i> , 103, 4091-4096 (1981)		
	B I	MAGNUS et al., "Synthetic and Mechanistic Studies on Esperamicin A ₁ and Calicheamicin γ_1 . Molecular Strain Rather Than π -Bond Proximity Determines the Cycloaromatization Rates of Bicyclo[7.3.1] Enediynes," <i>J. Am. Chem. Soc.</i> , 112, 4986-4987 (1990)		
	B J	MAIER, "Design of Enediyne Prodrugs," <i>Synlett</i> , 13-26 (1995)		
	B K	MARTHUR et al., "Cytosine Methylation Enhances DNA Damage Produced by Groove Binding and Intercalating Enediynes: Studies with Esperamicins A ₁ and C," <i>Biochemistry</i> , 36, 14868-14873 (1997)		
	B L	MINAMI et al., "Structure of an Aromatization Product of C-1027 Chromophore," <i>Tetrahedron Letters</i> , 34 (16), 2633-2636 (1993)		

Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number	09/913,924
Filing Date	August 20, 2001
First Named Inventor	Jeffrey M. ZALESKI
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	212691

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	BM	MYERS et al., "Design and Synthesis of a System of Eneidyne Formation by Anthraquinone Reductive Activation," <i>J. Am. Chem. Soc.</i> , 114, 5859-5860 (1992)		
	BN	MYERS et al., "Total Synthesis of (+)-Neocazinostatin Chromophore," <i>J. Am. Chem. Soc.</i> , 120, 5319-5320 (1998)		
	BO	KAPPEN et al., "Replication Block by an Eneidyne Drug-DNA Deoxyribose Adduct," <i>Biochemistry</i> , 38, 235-242 (1999)		
	BP	NICOLAOU et al., "Cyclic conjugated Eneidyne Related to Calicheamicins and Esperamicins: Calculations, Synthesis, and Properties," <i>J. Am. Chem. Soc.</i> , 110, 4866-4868 (1988)		
	BQ	NICOLAOU et al., "Synthesis and Chemistry of Dynemicin A Models," <i>J. Am. Chem. Soc.</i> , 113, 3106-3114 (1991)		
	BR	NICOLAOU et al., "Eneidyne Compounds equipped with Acid-, Base- and Photo-Sensitive Triggering Devices. Chemical Simulation of the Dynemicin A Reaction Cascade," <i>Angew. Chem. Int. Ed. Engl.</i> , 30 (8), 1032-1036 (1991)		
	BS	NICOLAOU et al., "Design, Synthesis, and Study of Simple Monocyclic Conjugated Eneidyne. The 10-Membered Ring Eneidyne Moiety of the Eneidyne Anticancer Antibiotics," <i>J. Am. Chem. Soc.</i> , 114, 7360-7371 (1992)		
	BT	NICOLAOU et al., "Redox-Controlled Bergman Cycloaromatizations. Designed Eneidyne with DNA-Cleaving Properties and Antitumor Activity," <i>J. Am. Chem. Soc.</i> , 114, 9279-9282 (1992)		
	BU	NICOLAOU et al., "Chemistry and Biology of Natural and Designed Eneidyne," <i>Proc. Natl. Acad. Sci. USA</i> , 90, 5881-5888 (1993)		
	BV	O'BRIEN et al., "Action Spectra of the Antileukemic and Antiviral Activities of Merocyanine 540," <i>Photochemistry and Photobiology</i> , 54 (5), 851-854 (1991)		


Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number 09/913,924
Filing Date August 20, 2001
First Named Inventor Jeffrey M. ZALESKI
Group Art Unit Unassigned
Examiner Name Unassigned
Attorney Docket Number 212691

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**


OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	BW	OSEROFF et al., "Strategies for Selective Cancer Photochemotherapy; Antibody-Targeted and Selective Carcinoma Cell Photolysis," <i>Photochemistry and Photobiology</i> , 46 (1), 83-96 (1987)		
	BX	PANDEY et al., "Porphyrin Dimers as Photosensitizers in Photodynamic Therapy," <i>J. Med. Chem.</i> , 33, 2032-2038 (1990)		
	BY	PANDEY et al., "Synthesis, Photophysical Properties, <i>in Vivo</i> Photosensitizing Efficacy, and Human Serum Albumin Binding Properties of Some Novel Bacteriochlorins," <i>J. Med. Chem.</i> , 40, 2770-2779 (1997)		
	BZ	RAMKUMAR et al., "Cyclization of Eneidyne Radical Cations through Chemical, Photochemical, and Electrochemical Oxidation: The Role of State Symmetry," <i>J. Org. Chem.</i> , 61, 2247-2250 (1996)		
	CA	RESSLER et al., "Creating New Photosensitizers for Cancer Therapy," <i>Chemtech</i> , 28 (3), 39-45 (1998)		
	CB	SCHREINER, "Cyclic Eneidyne: Relationship between Ring Size, Alkyne Carbon Distance, and Cyclization Barrier," <i>Chem. Commun.</i> , 483-484 (1998)		
	CC	SCHREINER, "Monocyclic Eneidyne: Relationships between Ring Sizes, Alkyne Carbon Distances, Cyclization Barriers, and Hydrogen Abstraction Reactions. Singlet-Triplet Separations of Methyl-Substituted <i>p</i> -Benzynes," <i>J. Am. Chem. Soc.</i> , 120, 4184-4190 (1998)		
	CD	SESSLER et al., "Texaphyrins: Synthesis and Applications," <i>Acc. Chem. Res.</i> , 27, 43-50 (1994)		
	CE	SHAIN et al., "The Synthesis and Reactivity of a Novel 10-Membered Azaenediynes," <i>Tetrahedron Letters</i> , 38 (34), 6067-6070 (1997)		

Examiner Signature _____ Date Considered _____

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

7

Application Number

Complete if Known

09/913,924

Filing Date

August 20, 2001

First Named Inventor

Jeffrey M. ZALESKI

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

212691

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C F	SHAIR et al., "The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Endiye Prodrug," <i>J. Am. Chem. Soc.</i> , 118, 9509-9525 (1996)		
	C G	SHIRAKI et al., "Visible Light Induced DNA Cleavage by the Hybrid Antitumor Antibiotic Dynemicin A," <i>Biochemistry</i> , 29, 9795-9798 (1990)		
	C H	SMITH et al., "The Enediye Antibiotics," <i>Journal of Medicinal Chemistry</i> , 39 (11), 2103-2117 (1996)		
	C I	SUGIURA et al., "DNA Intercalation and Cleavage of an Antitumor Antibiotic Dynemicin that Contains Anthracycline and Enediye Cores," <i>Proc. Natl. Acad. Sci. USA</i> , 87, 3831-3835 (1990)		
	C J	TURRO et al., "Photochemical Analogue of the Bergman Cycloaromatization Reaction," <i>Tetrahedron Letters</i> , 35 (44), 8089-8092 (1994)		
	C K	WARNER et al., "Controlled Acceleration and Inhibition of Bergman Cyclization by Metal Chlorides," <i>Science</i> , 269, 814-816 (1995)		
	C L	WELLS, "Cancer Gets the Red Light. Pharmacocycles, Inc.," <i>Chemistry & Biology</i> , 4 (10), 775-776 (1997)		
	C M	WENDER et al., "A Photochemically Triggered DNA Cleaving Agent: Synthesis, Mechanistic and DNA Cleavage Studies on a New Analog of the Antitumor Antibiotic Dynemicin," <i>J. Org. Chem.</i> , 58 (22), 5867-5869 (1993)		
	C N	WISNIEWSKI GRISSOM et al., "Determination of the Activation Parameters for the Bergman Cyclization of Aromatic Enediynes," <i>J. Org. Chem.</i> , 59, 5833-5835 (1994)		
	C O	XI et al., "Mechanistic Studies on the Base-Catalyzed Transformation of Neocarzinostatin Chromophore: Roles of Bulged DNA," <i>Biochemistry</i> , 38, 4342-4354 (1999)		


Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number	09/913,924
Filing Date	August 20, 2001
First Named Inventor	Jeffrey M. ZALESKI
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	212691

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	C P	XU et al., "Mechanism of Formation of Novel Covalent Drug DNA Interstrand Cross-Links and Monoadducts by Eneidyne Antitumor Antibiotics," <i>Biochemistry</i> , 36, 14975-14984 (1997)		
	C Q	XU et al., "DNA Damage Produced by Eneidyne in the Human Phosphoglycerate Kinase Gene in Vivo: Esperamicin A1 as a Nucleosome Footprinting Agent," <i>Biochemistry</i> , 37, 1890-1897 (1998)		
	C R	ZEIN et al., "Calicheamicin γ_1 : An Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically," <i>Science</i> , 240, 1198-1201 (1988)		
	C S	ZEIN et al., "Exclusive Abstraction of Nonexchangeable Hydrogens from DNA by Calicheamicin γ_1 ," <i>J. Am. Chem. Soc.</i> , 111, 6888-6890 (1989)		
	C T	ZEIN et al., "Calicheamicin γ_1 and DNA: Molecular Recognition Process Responsible for Site-Specificity," <i>Science</i> , 244, 697-699 (1989)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).